| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-05-3773 |
| P698 | PubMed publication ID | 16540683 |
| P50 | author | Darell D. Bigner | Q57195229 |
| Allan Friedman | Q4730609 | ||
| P2093 | author name string | Duane A Mitchell | |
| John H Sampson | |||
| James E Herndon | |||
| Peter E Fecci | |||
| John F Whitesides | |||
| Glenn Dranoff | |||
| Gary E Archer | |||
| Weihua Xie | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3294-3302 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma | |
| P478 | volume | 66 |
| Q42113451 | A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma |
| Q28731711 | A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma |
| Q38227889 | A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy |
| Q36973832 | A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells |
| Q37172697 | A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells |
| Q90273455 | A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol |
| Q37093633 | A prospective comparative clinical study of peripheral blood counts and indices in patients with primary brain tumors |
| Q54980235 | A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. |
| Q48879804 | Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin. |
| Q89823519 | Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma |
| Q27030863 | Adoptive cell therapies for glioblastoma |
| Q38921652 | Advances and challenges: dendritic cell vaccination strategies for glioblastoma. |
| Q38981383 | Advances in immunotherapy for the treatment of glioblastoma |
| Q27024830 | An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma |
| Q27011298 | Antibody, T-cell and Dendritic Cell Immunotherapy for Malignant Brain Tumors |
| Q34120472 | Antibody-based immunotherapy for malignant glioma |
| Q37483966 | Applications of neural and mesenchymal stem cells in the treatment of gliomas |
| Q39243060 | Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma |
| Q33578030 | Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM |
| Q30473731 | Association between cancer and contact allergy: a linkage study |
| Q50895317 | Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy |
| Q92373380 | Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases |
| Q33755077 | Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine |
| Q43223622 | Biomedical insights into cell adhesion and migration-from a viewpoint of central nervous system tumor immunology |
| Q38542113 | Brain Tumor Immunotherapy: What have We Learned so Far? |
| Q91736550 | Brain immunology and immunotherapy in brain tumours |
| Q89573873 | CAR T cells and checkpoint inhibition for the treatment of glioblastoma |
| Q58606449 | CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors |
| Q40619963 | CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells |
| Q55259532 | CNS cancer immunity cycle and strategies to target this for glioblastoma. |
| Q36922514 | CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes |
| Q37986999 | Cancer Immunoediting in Malignant Glioma |
| Q48769325 | Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion |
| Q38151738 | Cancer immunotherapy: accomplishments to date and future promise |
| Q35829972 | Cancer stem cells in glioblastoma |
| Q64946311 | Cell lines and immune classification of glioblastoma define patient's prognosis. |
| Q35821404 | Cellular-based immunotherapies for patients with glioblastoma multiforme. |
| Q37640613 | Challenges in clinical design of immunotherapy trials for malignant glioma |
| Q28066906 | Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System |
| Q47719808 | Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. |
| Q39100186 | Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study |
| Q33668575 | Clinical applications of a peptide-based vaccine for glioblastoma. |
| Q38094811 | Clinical trials in cellular immunotherapy for brain/CNS tumors |
| Q33570549 | Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice |
| Q39160992 | Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma |
| Q37179415 | Combating immunosuppression in glioma |
| Q38422623 | Combining immunotherapy with radiation for the treatment of glioblastoma |
| Q58797848 | Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials |
| Q39449408 | Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma |
| Q60046462 | Current Options and Future Directions in Immune Therapy for Glioblastoma |
| Q38094808 | Current and future directions for Phase II trials in high-grade glioma |
| Q37861631 | Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development |
| Q37240292 | De novo induction of genetically engineered brain tumors in mice using plasmid DNA |
| Q38358028 | Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development |
| Q46412180 | Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. |
| Q55257766 | Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. |
| Q38912265 | Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response |
| Q64992983 | Dendritic cell vaccines for high-grade gliomas. |
| Q36764903 | Dendritic cell-based active specific immunotherapy for malignant glioma |
| Q39842438 | Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy |
| Q47809269 | Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells |
| Q35863183 | Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma |
| Q33328253 | Dietary prevention of malignant glioma aggressiveness, implications in oxidant stress and apoptosis. |
| Q38776701 | Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion. |
| Q33772507 | Disruption of TGF-beta signaling prevents the generation of tumor-sensitized regulatory T cells and facilitates therapeutic antitumor immunity. |
| Q90705896 | Downregulation of FOXP3 in neutrophils by IL-8 promotes the progression of oral squamous cell carcinoma |
| Q33410400 | Dynamics of central and peripheral immunomodulation in a murine glioma model |
| Q37259602 | EGF receptor variant III as a target antigen for tumor immunotherapy |
| Q37618652 | EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. |
| Q42739222 | Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial". |
| Q39896275 | Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function |
| Q38953017 | Embracing rejection: Immunologic trends in brain metastasis |
| Q37025105 | Emerging immunotherapies for glioblastoma |
| Q36017728 | Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet |
| Q38943301 | Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells |
| Q36484129 | Epigenetic biomarkers of T-cells in human glioma. |
| Q40847481 | Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators |
| Q39686208 | Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity |
| Q41085695 | First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity |
| Q26774997 | Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept |
| Q35162266 | Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care. |
| Q35783111 | Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. |
| Q37316117 | Genetically engineered T cells to target EGFRvIII expressing glioblastoma |
| Q38362051 | Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies |
| Q97067664 | Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression |
| Q38516823 | Glioblastoma antigen discovery--foundations for immunotherapy. |
| Q34129168 | Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway |
| Q35122209 | Glioblastoma extracellular vesicles: reservoirs of potential biomarkers |
| Q38355702 | Glioblastoma stem cells and stem cell-targeting immunotherapies. |
| Q39474593 | Glioblastoma-induced inhibition of Langerhans cell differentiation from CD34(+) precursors is mediated by IL-6 but unaffected by JAK2/STAT3 inhibition |
| Q34147415 | Glioma-associated cancer-initiating cells induce immunosuppression |
| Q36705896 | Glioma-derived extracellular vesicles selectively suppress immune responses |
| Q36690281 | Glioma-specific antigens for immune tumor therapy |
| Q37092938 | Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages |
| Q39285687 | HO-1 Induction in Cancer Progression: A Matter of Cell Adaptation |
| Q64110950 | Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma |
| Q37492175 | Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial |
| Q37598477 | Heme oxygenase-1 protects regulatory T cells from hypoxia-induced cellular stress in an experimental mouse brain tumor model. |
| Q89967023 | High Dimensional Mass Cytometry Analysis Reveals Characteristics of the Immunosuppressive Microenvironment in Diffuse Astrocytomas |
| Q37598166 | Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody |
| Q36405905 | IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival |
| Q59134964 | Imbalance of immunological synapse-kinapse states reflects tumor escape to immunity in glioblastoma |
| Q38989773 | Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy |
| Q26765459 | Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium |
| Q58573409 | Immune Checkpoints and Innovative Therapies in Glioblastoma |
| Q55261256 | Immune Microenvironment in Glioblastoma Subtypes. |
| Q47135965 | Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas. |
| Q38712457 | Immune microenvironment of gliomas |
| Q36120388 | Immune phenotypes predict survival in patients with glioblastoma multiforme. |
| Q37154132 | Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. |
| Q34676437 | Immune therapeutic targeting of glioma cancer stem cells |
| Q37420586 | Immune-checkpoint blockade and active immunotherapy for glioma |
| Q34558393 | Immunologic targeting of FOXP3 in inflammatory breast cancer cells. |
| Q38870994 | Immunological Aspects of Malignant Gliomas |
| Q26746612 | Immunological Evasion in Glioblastoma |
| Q37011021 | Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study |
| Q47660305 | Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. |
| Q36224048 | Immunosuppressive mechanisms in glioblastoma |
| Q47100447 | Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity |
| Q37267793 | Immunotherapeutic approaches for glioma |
| Q47915209 | Immunotherapies for malignant glioma. |
| Q40471303 | Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity |
| Q55462587 | Immunotherapy Trials for Glioblastoma Multiforme: Promise and Pitfalls |
| Q26866513 | Immunotherapy advances for glioblastoma |
| Q34480557 | Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma? |
| Q91199920 | Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons |
| Q35114086 | Immunotherapy for malignant glioma |
| Q36224057 | Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy |
| Q27002510 | Immunotherapy for primary brain tumors: no longer a matter of privilege |
| Q37980026 | Immunotherapy for the Treatment of Glioblastoma |
| Q37925259 | Immunotherapy in human glioblastoma |
| Q34701587 | Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions |
| Q34140756 | Immunotherapy of Malignant Gliomas Using Autologous and Allogeneic Tissue Cells |
| Q36162929 | Immunotherapy of malignant brain tumors |
| Q37608106 | Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper |
| Q35020804 | Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cells |
| Q41966303 | Immunovirotherapy for the treatment of glioblastoma. |
| Q40529135 | Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment |
| Q64928237 | Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. |
| Q41101153 | Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue |
| Q36139736 | Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors. |
| Q38925761 | Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model |
| Q34496174 | Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy |
| Q42592309 | Infiltrating CTLs in human glioblastoma establish immunological synapses with tumorigenic cells |
| Q28383820 | Inherited variation in immune genes and pathways and glioblastoma risk |
| Q35440540 | Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System. |
| Q43166491 | Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study |
| Q42290425 | Interleukin 21 inhibits cancer-mediated FOXP3 induction in naïve human CD4 T cells |
| Q36710917 | Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma |
| Q90218743 | Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas |
| Q92856193 | LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression |
| Q38365590 | Liquid biopsies in patients with diffuse glioma |
| Q40241735 | Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination |
| Q61811189 | Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma |
| Q37869493 | Mechanisms of immunomodulation in human glioblastoma. |
| Q37968929 | Medulloblasoma: challenges for effective immunotherapy |
| Q36785139 | MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints |
| Q38013713 | Monoclonal Antibody Therapy For Malignant Glioma |
| Q35220386 | Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans |
| Q36584178 | Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant |
| Q37031739 | Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model |
| Q90147865 | Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma |
| Q38161536 | Myeloid-derived suppressor cells in glioma |
| Q37727645 | Myeloid-derived suppressor cells in gliomas |
| Q46675575 | Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. |
| Q34132823 | Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. |
| Q34189694 | Overview of cellular immunotherapy for patients with glioblastoma. |
| Q26776345 | Overview of current immunotherapeutic strategies for glioma |
| Q36493843 | PD-L1 expression and prognostic impact in glioblastoma |
| Q98784867 | Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity |
| Q38013716 | Peptide Vaccine |
| Q55466316 | Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes. |
| Q47967074 | Pre-treatment lymphopenia and indication of tumor-induced systemic immunosuppression in medulloblastoma |
| Q64060934 | Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme |
| Q33887213 | Prognostic value of the preoperative immunological profile in patients with glioblastoma |
| Q28081371 | Prospects of immune checkpoint modulators in the treatment of glioblastoma |
| Q37159215 | Proteomic and immunologic analyses of brain tumor exosomes |
| Q57798069 | RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma |
| Q64279738 | Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study |
| Q38398440 | ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. |
| Q35992355 | Recent developments on immunotherapy for brain cancer |
| Q33761585 | Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. |
| Q38955193 | Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. |
| Q38616499 | Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). |
| Q42554303 | Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. |
| Q35789008 | Regulatory T cells are not a strong predictor of survival for patients with glioblastoma |
| Q41871348 | Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody |
| Q38020963 | Regulatory T cells in the central nervous system |
| Q36872066 | Regulatory T cells move in when gliomas say "I Do". |
| Q41198335 | Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients |
| Q92881504 | Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma |
| Q38051323 | Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma |
| Q21129255 | Role of exosomes/microvesicles in the nervous system and use in emerging therapies |
| Q30491742 | Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma |
| Q90929525 | Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors |
| Q36558234 | Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. |
| Q33746041 | Single vs. combination immunotherapeutic strategies for glioma. |
| Q95841008 | Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma |
| Q37109246 | Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas |
| Q48220006 | Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function |
| Q36255674 | Systemic T Cells Immunosuppression of Glioma Stem Cell-Derived Exosomes Is Mediated by Monocytic Myeloid-Derived Suppressor Cells. |
| Q41826343 | Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone |
| Q37438563 | Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines |
| Q50043938 | T Cell Exhaustion Signatures Vary with Tumor Type and are Severe in Glioblastoma |
| Q52625023 | T-Cell Dysfunction in Glioblastoma: Applying a New Framework. |
| Q34082913 | T-cell TGF-β signaling abrogation restricts medulloblastoma progression. |
| Q59137521 | T-cell exhaustion in glioblastoma |
| Q36297064 | Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. |
| Q92511358 | Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors |
| Q38110540 | Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. |
| Q37030810 | Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma |
| Q28072012 | Targeting immune checkpoints in malignant glioma |
| Q53686926 | Temozolomide for Immunomodulation in the Treatment of Glioblastoma. |
| Q39178065 | The Microenvironmental Landscape of Brain Tumors |
| Q37475929 | The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients |
| Q35886554 | The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients |
| Q55456844 | The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma. |
| Q26797282 | The progress of immunotherapy for glioblastoma |
| Q36571197 | The role of checkpoints in the treatment of GBM |
| Q89813020 | The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction |
| Q38540262 | The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression |
| Q39045958 | The role of the immune system in neurofibromatosis type 1-associated nervous system tumors |
| Q37452411 | The role of tregs in glioma-mediated immunosuppression: potential target for intervention. |
| Q39521993 | The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies |
| Q35871559 | The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. |
| Q37307810 | Therapeutic vaccines for malignant brain tumors |
| Q35570260 | Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors |
| Q37533657 | Toward effective immunotherapy for the treatment of malignant brain tumors |
| Q33330270 | Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials |
| Q91868339 | Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma |
| Q37598949 | Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses |
| Q41062315 | Tumor-Associated Macrophages in Glioma: Friend or Foe? |
| Q90251860 | Tumor-derived exosomes in the regulation of macrophage polarization |
| Q42789833 | Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class |
| Q37186248 | Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma |
| Q37411109 | Tumour vaccine approaches for CNS malignancies: progress to date. |
| Q64075498 | Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers |
| Q38243975 | Vaccine therapies for patients with glioblastoma |
| Q57160349 | Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives |
| Q38789860 | Vaccine-based immunotherapeutic approaches to gliomas and beyond |
| Q38233114 | Vaccine-based immunotherapy for glioblastoma |
| Q35799695 | Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. |
| Q42563520 | miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma |
| Q37420546 | yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. |
Search more.